Skip to main content
. 2021 Apr 1;42(13):1216–1227. doi: 10.1093/eurheartj/ehab094

Figure 5.

Figure 5

Effect of sodium-glucose co-transporter 2 inhibitors on mortality in three clinical trials in patients with chronic kidney disease. Cardiovascular death was a component of the primary outcome in all trials. Because of loss of funding in the SCORED trial (sotagliflozin) not all endpoints were adjudicated and only investigator-reported endpoints were published. Data extracted from the CREDENCE (canagliflozin) and SCORED publications.7,17,19 Relative risk ratios are presented for SCORED since hazard ratios could not be extracted. *In all trials undetermined causes of death were assumed to be of cardiovascular cause and were combined with cardiovascular causes of death. Quantitative assessment of effect on all-cause mortality and each cause of death was made by random-effects meta-analysis and calculating P-value for heterogeneity of the individual trial results. Summary statistics across trials are not provided because of heterogeneity for all-cause mortality and non-cardiovascular death.